Essas são algumas das referências.

Profissionais de saúde: clique aqui e solicite mais informações.

 

[1] Instrução ao paciente Capecitabina (Xeloda – Roche), Sunitinibe (Sutent - Pfizer), Sorafenib (Nexavar - Bayer).

[2] Yale Cancer Center - Aplicação do Udderly em variação da Síndrome Mão-Pé (grau 3) em paciente com Deficiência Dihidropirimidina Desidrogenase. Clin Colorectal Cancer. 2006 Sep;6(3):219-23.PMID:17026792

[3] Identifying and Treating Fluoropyrimidine Associated Hand-and-Foot Syndrome in White and Non-White Patients. Muhammad Wasif Saif, MD, MBBS, and Aymen A. Elfiky, MD (Yale University School of Medicine)

[4] Phase I Study of Capecitabine With Concomitant Radiotherap - ASCO American Society of Clinical Oncology

[5] Sorafenib-induced Hand- Foot Skin Reaction Treatment. Northwestern University. NCT00667589

[6] Handbook of Cancer Chemotherapy. By Roland T. Skeel, Samir Khleif

[7] Breast Cancer Breakthroughs:Living Longer / Avanços sobre o Câncer de Mama: Vivendo Mais. Sattar Memon

[8] The Chemotherapy Survival Guide: Everything You Need to Know, Judith McKay, Tammy Schacher

[9] Atlas of Breast Surgery, Jatoi, .Kaufmann,J.Y.Petit

[10] Cancer Symptom Management, 3rdEdition Connie Henke Yarbro, Margaret Hansen Frogge, Michelle Goodman

[11] Journal of Clinical Oncology vol.23 No.34, American Society of Clinical Oncology (ASCO)

[12] Journal of Oncology Pharmacy Practice. Sept 2006, vol.12,3: pp.131-141 e December 2003 vol. 9, 4. pp. 161-163

[13] The Journal of Supportive Oncology Volume 5 number 7

[14] Livro Seguredos em Enfermagem Oncológica - Respostas Necessárias ao Dia-a-Dia, Rose A. Gates

[15] Northwestern University (NCT:006758920100402) Comparação do Udderly com ureia 40%, fluocinonide 0.05% (corticoide), e tazarotene 0.1%.